INTRODUCTION
Ceruletide is the international nonproprietary name of caerulein, a decapeptide originally isolated from the skin of the Australian frog Hyla caerulea more than 30 years ago (2) . Although caerulein does not exist in mammals, including humans, it closely resembles cholecystokinin octapeptide (CCK-8) in the C-terminal amino acid sequence ( Fig. 1 ) and possesses a virtually identical spectrum of biological activities. Because ceruletide induces a variety of CCK-8-like effects on the digestive organs (e.g., stimulation of gallbladder contraction, pancreatic enzyme secretion, and intestinal motility), it was initially thought to be potentially useful for examining digestive functions and treating intestinal disease (100) . Actually, ceruletide has been clinically used in cholecystography (80) .
Since the discovery of CCK-containing neurons in the brain by Vanderhaeghen et al. (95) in the mid-1970s, the interest in CCK has primarily focused on its physiological roles in the CNS. Evidence for the coexistence of CCK and dopamine in the midbrain neurons, as demonstrated by Hökfelt et al. (33, 34) , had a striking influence on the subsequent investigations in this field. This evidence led to an intriguing hypothesis that CCK may be a neuromodulator of dopaminergic functions in the mesolimbic systems. Numerous studies have focused on the interaction between CCK and dopamine, which suggested that exogenously administered CCK and its related compounds might possibly modulate dopaminergic activity (85, 94) . Accordingly, ceruletide has been considered to be a candidate as a new treatment of neuropsychiatric disease, in which pathophysiological dopaminergic dysfunction has been assumed to exist. Moreover, in the early 1980s, Zetler (103, 104) reported a variety of behavioral effects of ceruletide in mice (e.g., the induction of sedation, catalepsy, ptosis, and hypothermia, and the antagonism of nociception, methylphenidate-induced stereotypy, picrotoxin-induced convulsions and indole alkaloids-ceruletide is similar to that of CCK-8 and differs only in the substitution of Thr 5 for Met 3 of CCK-8 ( Fig. 1 ). This C-terminal amino acid sequence has biological activity because deamidation or shortening of the peptide chain to a C-terminal pentapeptide reduced or abolished the potency in all respects. The sulfated residue of Tyr 3 also plays an important role in the biological action because of the lack of activity in desulfated ceruletide. This biological active structure may be associated with the affinity of ceruletide for CCK receptors (18, 90) . The affinities of ceruletide for CCK receptor subtypes are almost equal to those of CCK-8, as determined by displacing the binding of [ 3 H]CCK-8 to rat cerebral cortex (CCK B receptor: IC 50 = 1.6 nM) and pancreas (CCK A receptor: IC 50 = 0.3 nM) (96) . Ceruletide thus has a low selectivity for either receptor subtype alone. Regarding its behavioral effects in mice, ceruletide was reported to be more potent than CCK-8 with some exceptions (104) .
PHARMACOLOGY

Sites of Actions of Ceruletide
The sites of the central actions of peripherally administered ceruletide have long been the most controversial issue. Due to the rapid degradation in the periphery and minimal permeability through the blood-brain barrier (BBB), an intravenously administered peptide has been thought to hardly reach the brain. Studies on the ability of peripherally administered CCK-8 to enter the cerebrospinal fluid showed that exogenous CCK did not cross the BBB to a considerable extent (4, 105 was reported to antagonize some of the behavioral and neurochemical effects of ceruletide (21, 23, 43, 98) , the vagal afferent pathway to the nucleus tractus solitarii has been considered to be the major site of the central actions of peripherally administered ceruletide (11) . It is, however, unlikely that all the effects of ceruletide might be attributed to the actions on the vagal nerves in the visceral organs (22, 63) . Some studies have suggested the possibility that exogenous CCK acts directly at specific brain regions (35) . The possible involvement of the hypothalamo-pituitary systems has also been suggested to account for this issue (55) . The results of the BBB penetration studies might have been inconclusive if the assays used in these studies were not sensitive enough to detect small but effective concentrations of the peptide in the brain (76) . The identification of two subtypes of CCK receptors helped to resolve this problem (30, 61) . The CCK A receptors are located in the peripheral organs and are also seen in restricted brain regions, including the nucleus tractus solitarii, area postrema, interpeduncular nucleus, and posterior hypothalamic nuclei. CCK B receptors are widely distributed throughout the brain. The development of selective nonpeptide antagonists for CCK A and CCK B receptors has now enabled us to determine whether and how exogenously administered CCK exerts its central effects (101) . Ceruletide nonselectively binds to both CCK A and CCK B receptors. To date, at least three sites and routes of actions of peripherally administered ceruletide have been considered (Fig. 2) . First, as previously suggested, ceruletide may primarily act on CCK A receptors in the visceral organs to exert central actions via the vagal afferent nerves. Second, ceruletide may also act on CCK A receptors in specific brain regions, such as the area postrema, where circulating peptides easily enter the brain through the porous BBB (61) . The effects mediated by these sites would be blocked by CCK A receptor antagonists but not by a subdiaphragmatic vagotomy alone. Third, despite the minimal permeability through the BBB, a very small amount of ceruletide may enter the brain and directly act on CCK B receptors. The effects mediated via these sites would be selectively antagonized by CCK B receptor antagonists. Due to these multiple sites and routes of action, the central effects of ceruletide appear to be very ambiguous and complicated. Moreover, it is possible that the stimulation of different receptor subtypes by ceruletide may produce an opposite effect on each other (12, 52) . Such receptor-mediated interactions could thus contribute to the higher integration of CCK-involved functions.
Interactions with Dopaminergic Functions
Effects on Dopamine-Mediated Behaviors
Because CCK coexists with dopamine in midbrain neurons, behavioral studies of CCK-dopamine interactions have focused on rodent behaviors known to be mediated by midbrain dopaminergic projections. Studies of the effects of ceruletide and CCK-8 on dopamine-mediated behaviors have varied extensively in regard to dose (pg, ng, or µg) and route of administration (s.c., i.p., i.c.v., or locally into the discrete brain regions). These variations in experimental conditions resulted in only partially consistent results. Recent studies employing the selective CCK-receptor-subtype antagonists have led to further elucidation of the behavioral interactions of ceruletide with dopamine.
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When peripherally administered to rodents, high doses (µg order) of ceruletide produced catalepsy, which is similar to that induced by antipsychotic drugs such as haloperidol, had inhibitory effects on spontaneous locomotor activity and dopamine agonist-induced hyperlocomotion, and also attenuated electrical self-stimulation and reinforced operant responding (14, 19, 24, 43, 52, 62, 97, 103, 104) . These data suggest that peripherally administered ceruletide has an inhibitory effect on dopaminergic behaviors. Some of these effects may be due to the stimulation of CCK A receptors, most likely in the periphery, because of the activity of CCK A receptor antagonists and a subdiaphragmatic vagotomy (14, 19, 24, 97, 98) . However, devazepide, a CCK A receptor antagonist, and L-365,260, a CCK B receptor antagonist, modulated the effects of ceruletide on dopamine agonist-induced behaviors in mice in a different manner (52) . Another study reported that a subdiaphragmatic vagotomy failed to inhibit the effects of ceruletide on spontaneous and dopamine agonist-induced locomotor activities in mice (63) . These results suggest the possible involvement of not only CCK A receptors but also CCK B receptors in the mechanisms of the behavioral effects of ceruletide.
The central administration of low doses (pg or ng order) of ceruletide, as well as CCK-8, produced more conflicting results. Bilateral injections of ceruletide into the nucleus accumbens inhibited hypolocomotion in rats induced by injections of low doses of apomorphine into the nucleus accumbens. However, injections of ceruletide into the nucleus accumbens had no effect on hyperlocomotion in rats induced by injections of either dopamine or high doses of apomorphine into the nucleus accumbens (25) . While s.c. and i.c.v. administration of ceruletide inhibited electrical self-stimulation in rats, injection of ceruletide into the nucleus accumbens had no effect (24) . Discrepancies in the behavioral effects of centrally administered ceruletide may be in part due to regional differences in the distribution and functions of CCK receptors. Crawley (12) suggests that the interactions of CCK with the mesolimbic dopaminergic pathway may reflect the distinct distribution of CCK-receptor subtypes in the subregions of the nucleus accumbens (Fig. 3) . In the medial posterior nucleus accumbens receiving the projection of CCK-dopamine coexisting neurons, CCK may potentiate dopaminergic behaviors by stimulating CCK A receptors. In contrast, CCK may inhibit dopaminergic behaviors via CCK B receptors in the anterior nucleus accumbens, where CCK and dopamine exist primarily in separate terminals. The paradigm of this hypothesis may be useful for understanding the mechanisms of the complicated actions of ceruletide.
Tolerance to the behavioral effects of ceruletide in mice developed following repeated administration (99) . On the other hand, the ability of amphetamine to stimulate locomotor activity increased after the repeated administration of ceruletide. While the concomitant administration of ceruletide with methamphetamine attenuated the development of methamphetamine sensitization in mice, ceruletide did not inhibit the induction of methamphetamine sensitization as provoked by a challenge injection of methamphetamine (48) .
It should be noted that some studies reported long-lasting effect after a single administration of ceruletide on dopaminergic behaviors. The combination of ceruletide with haloperidol produced a long-lasting inhibitory effect on amphetamine-induced hyperlocomotion in rats for at least up to 14 d after a single injection of both drugs (55) , although this effect was not later replicated (66) . Another study showed that ceruletide, administered 24 h prior to the dopamine D 1 -receptor agonist SKF 38393, attenuated SKF 38393-induced grooming behavior in rats (54) . Studies in animal models of dyskinesia also reported similar long-lasting effects of ceruletide (3, 74, 75) , as described later in this review.
These phenomena may be relevant to the long-lasting effect of ceruletide on clinical subjects, yet the mechanisms by which ceruletide exerts such long-lasting effects remain to be determined.
Neurochemical Interactions with Dopamine
An early study reported an inhibitory effect of ceruletide in vivo on dopamine metabolism in the striatum (56) . Since the late 1980s, in vivo microdialysis studies have explored the regional effects of ceruletide on dopamine release in the rat brain (Table 1) .
One study reported that ceruletide decreased basal dopamine release in the striatum, and this effect was blocked by a subdiaphragmatic vagotomy (23) . However, other studies reported that ceruletide had no effect on basal dopamine release in the striatum but decreased haloperidol-induced dopamine release under the high K + concentrations in the perfusate (41) . The local application of ceruletide via a dialysis probe produced a similar effect. Moreover, the CCK B receptor antagonist L-365,260, but neither the subdiaphragmatic vagotomy nor the CCK A receptor antagonist L-364,718, antagonized this effect (42) . These data suggest that peripherally administered ceruletide could produce an inhibitory effect on striatal dopamine release under appropriate depolarization via the direct action on CCK B receptors in the striatum. Ceruletide also attenuated the medial forebrain bundle stimulated-dopamine release in combination with the high K + concentrations in the perfusate, although ceruletide did not affect this release under lower K + concentrations (44) . Ceruletide may thus further depolarize the striatal dopamine terminals and induce CNS Drug Reviews, Vol. 5, No. 2, 1999 
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T. KUROKI ET AL. depolarization inactivation of the nigrostriatal dopamine neurons. This inhibitory effect on the nigrostriatal dopaminergic activity may contribute to the reported efficacy of ceruletide on tardive dyskinesia. On the other hand, ceruletide attenuated amphetamine-induced dopamine release in the nucleus accumbens but not in the striatum (43) . This neurochemical effect was consistent with the behavioral effect of ceruletide to inhibit amphetamine-induced hyperlocomotion but not stereotyped behaviors. The inhibitory effect of ceruletide on amphetamine-induced dopamine release in the nucleus accumbens may be due to the stimulation of CCK A receptors because it was completely abolished by a subdiaphragmatic vagotomy (43) . Based on the above findings, ceruletide may have a differential effect on dopamine release in the striatum and the nucleus accumbens via different receptor subtypes.
In the medial prefrontal cortex, ceruletide produced an increase in extracellular levels of dopamine and its metabolites (21) . These effects were incompletely attenuated by a subdiaphragmatic vagotomy and were completely prevented by the CCK A -receptor antagonist L-364,718. Local application of ceruletide into the medial prefrontal cortex had no effect on extracellular dopamine metabolite levels. These results suggest that peripherally administered ceruletide may increase basal dopamine release in the medial prefrontal cortex via CCK A receptors. When phencyclidine, a psychotomimetic drug, preferentially increased dopamine release in the prefrontal cortex, ceruletide attenuated this increase (17) . This effect was compatible with the inhibitory effect of ceruletide on phencyclidineinduced increases in tissue dopamine metabolite levels in the medial prefrontal cortex (49) . The CCK B receptor antagonist PD 135,158 reversed the inhibitory effect of ceruletide on phencyclidine-induced dopamine release, suggesting the involvement of CCK B re-CERULETIDE 151 ceptors in the ceruletide-PCP interactions (17) . Ceruletide may thus have a differential effect on basal and phencyclidine-induced dopamine release in the medial prefrontal cortex by the stimulation of different receptor subtypes. Recently, prefrontal dopaminergic functions have been related to such cognitive functions as working memory (67) . Phencyclidine is known to produce psychosis that closely resembles positive and negative symptoms and cognitive impairment of schizophrenia. The preferential activation of prefrontal dopamine neurons by phencyclidine may be related to the cognitive impairment associated with phencyclidine-induced psychosis, because ketamine, a phencyclidine-related compound, was also reported to produce cognitive impairment in healthy humans and increase prefrontal dopamine release (59) . Interestingly, ceruletide inhibited the behavioral responses to ketamine in mice (47, 93) . These considerations suggest the possibility that the modulatory effects of ceruletide on prefrontal dopaminergic activity would be effective in the treatment of the cognitive impairment of neuropsychiatric disease.
Interactions with Amino Acidergic Neurons
The intraperitoneal administration of ceruletide increased basal and K + -evoked acetylcholine release in the striatum of rats in vivo (83) . Modulatory effects of the peptide on acetylcholine release from the cerebral cortex were also reported (51). Ceruletide decreased γ-aminobutyric acid (GABA) concentrations and GABA turnover rates, as measured by GABA accumulation following the inhibition of GABA transaminase by aminooxyacetic acid, in the nucleus accumbens, striatum, and substantia nigra (68, 70) . Interactions between acetylcholine and GABA in the nigrostriatal dopaminergic systems may be involved in the mechanisms of the motor effects of ceruletide.
In vitro studies using neuron cultures reported that ceruletide has a neuroprotective effect against excitatory amino-acid-induced neurotoxicity. When applied to rat neuron cultures, ceruletide and CCK-8 reduced glutamate-and N-methyl-D-aspartate (NMDA)-induced neuronal cell death, based on measurements of the efflux of lactate dehydroxylase into the culture medium (1, 40, 84, 91) . Ceruletide also decreased glutamate-induced depolarization in the slices of rat cerebral cortex (28) . Most studies consistently show that the neuroprotective effects could be mediated by CCK B receptors. Ceruletide administered s.c. prior to ischemia attenuated delayed neuronal cell death in the hippocampal CA1 area following ischemic changes induced by 5-min occlusion of the bilateral carotid arteries of Mongolian gerbils (16) . Concurrently, ischemia-induced hyperlocomotion and amnestic behaviors in gerbils 24 h after ischemia were attenuated. These results suggest that ceruletide may have a therapeutic potential in neurodegenerative disease.
Effects on Animal Models of Neuropsychiatric Disease
Models of Dyskinesia
Due to the inhibitory effects of peripherally administered ceruletide on dopaminergic behaviors in animals and the dopamine hypothesis of schizophrenia, this peptide was initially developed as an antipsychotic drugs (60, 69 inhibitory effects of peripherally administered ceruletide on striatal dopaminergic activity in rats have led to the hypothesis that it would be effective in the treatment of tardive dyskinesia (23, 41, 56) because the dopaminergic supersensitivity of the nigrostriatal systems following long-term antipsychotic treatment may be the basis for the pathophysiology of this disorder (20) . Together with clinical trials, the effects of ceruletide on dyskinesia have been investigated in a number of experimental animal models. Repeated administration of iminodipropionitrile, a neurotoxin, to rats produced persistent abnormal behaviors such as head-twitching, random circling, and hyperactivity. Single administration of ceruletide reduced vertical head-twitching in iminodipropionitrile-treated rats for over 5 h after injection (74) . Subsequent repeated administration of ceruletide maintained the inhibitory effect on iminodipropionitrile-induced dyskinesia for longer periods. Changes in several neurochemical variables, such as dopamine D 1 -and D 2 -receptor mRNAs in the striatum, closely correlated with the motor effects of ceruletide (31) .
Chronic treatment with the antipsychotic drug fluphenazine produced perioral movements in rats, together with increases in dopamine D 1 receptor binding and dopamine-receptor-coupled adenylate cyclase activity in the striatum (3). Repeated administration of ceruletide for 3 d abolished the perioral movements and reversed the increases in both D 1 -receptor binding and dopamine-stimulated adenylate cyclase activity to the control level. These effects continued for 6 d after the last injection of ceruletide. These data suggest that ceruletide may thus improve dyskinesia through the D 1 -receptor-mediated mechanism.
Ceruletide, locally injected into the posterior nucleus accumbens, increased apomorphine-induced jaw movements in rats after spinal transection (46) . The potentiation of ceruletide was prevented by the concomitant injection of the CCK A receptor antagonist, lorglumide. This finding suggests that CCK A receptors in the nucleus accumbens may be involved in the pathophysiology of oral dyskinesia.
A study in nonhuman primates reported that intramuscular injection of ceruletide inhibited L-DOPA-induced dyskinesia in monkeys with unilateral ventromedial tegmental lesions (75) . This effect was maintained for at least 9 d after a single injection of ceruletide. A local injection of dopamine into the ipsilateral caudate nucleus immediately produced severe dyskinesia in the contralateral extremities of the monkey. However, ceruletide, directly injected into the caudate nucleus prior to dopamine, completely prevented dopamine-induced dyskinesia. This effect continued for at least 5 d. Although these are preliminary data, the effect of ceruletide on dopamine-agonist-induced dyskinesia in lesioned monkeys closely resembles the reported clinical effect in humans.
It should be noted that most of these studies reported on the long-lasting effects of ceruletide on dyskinesia in model animals (3, 74, 75) . These findings are consistent with clinical findings that ceruletide-induced amelioration of dyskinesia was maintained for over 1 w following a single injection. Moreover, ceruletide-induced neurochemical changes (e.g., monoamine turnover and receptor expression) were found more prominently in model animals than in normal controls (31, 74) . It is, therefore, conceivable that ceruletide, even at low concentrations, could exert a modulatory effect to restore pathological changes to normal levels, while it may have a modest effect on the normal steady state.
Models of Anxiety
CCK has been suggested to play an important role in anxiogenic mechanisms. CCK-4, a selective CCK B -receptor agonist, induces anxiety-related responses (8, 79) , whereas the CCK B -receptor antagonists have been reported to have anxiolytic effects (36) . The effect of ceruletide on anxiety was examined in rodents using an elevated plus maze test. Nonsedative doses of ceruletide decreased exploratory activity in mice and rats on an elevated plus maze, indicating that ceruletide has an anxiogenic effect (26, 52) . This effect was not prevented by a subdiaphragmatic vagotomy (98) . Low doses of diazepam were ineffective on ceruletide-induced suppression of exploratory activity. Nonsedative doses of CCK-4 also decreased the exploratory activity in rats, and this effect was antagonized by the CCK B -receptor antagonist (27) . These data suggest that ceruletide elicits an anxiogenic effect by stimulating CCK B receptors. However, the effect of CCK on exploratory behaviors might reflect motivational and reward mechanisms (i.e., CCK-dopamine interactions in the limbic reward systems) rather than anxiogenic mechanisms (12, 13) .
Effects on Memory and Cognitive Functions
CCK may influence certain aspects of the memory and learning process. A series of studies on various experimental paradigms of memory performance suggests that ceruletide has a protective effect on memory impairment. Subcutaneous administration of ceruletide prevented memory impairment of rats in active avoidance tasks, in passive avoidance tasks induced by electroconvulsive shock or protein kinase C inhibitors, and in Morris water maze tasks induced by protein synthesis inhibitors or vasoactive intestinal peptide (37, 38, 88, 89) . Ceruletide also attenuated carbon monoxide-induced impairment of memory performance in mice in both Y-maze tasks and passive-avoidance tasks (58). Both s.c. and i.c.v. administration of ceruletide prevented amnesia in mice. While both L-364,782 and L-365,260 partially blocked the effect of peripherally administered ceruletide, L-365,260 selectively and completely antagonized the effect of centrally administered ceruletide. These data suggest two different antiamnestic mechanisms -ceruletide operates through peripheral CCK A receptors and central CCK B receptors. The effect of ceruletide on memory performance in experimental animals seems to depend on the test paradigms.
Recently, electrophysiological studies have investigated the influence of ceruletide on memory and cognitive functions in humans. Ceruletide has been shown to affect certain components of the auditory-evoked potentials to tone stimuli in humans, thus suggesting that ceruletide may affect selective attention (77, 82) . It is noteworthy that ceruletide enhanced the P3 component of the evoked potentials, an indicator of memory processing, in young but not in elderly subjects (15) . Administration of ceruletide to hungry human subjects diminished recall and recognition of food stimuli (78) . Because similar responses occurred after food intake, ceruletide may influence the memory process relating to food intake; however, the P3 component of the evoked potentials did not indicate that ceruletide has an effect on memory of food stimuli. Interestingly, ceruletide produced a selective and long-lasting increase in the theta component of the evoked potentials in the hippocampus of cats (5) . Considering the essential role of the hippocampus in memory processing, this response may be related to the above-mentioned antiamnestic effect of CNS Drug Reviews, Vol. 5, No. 2, 1999 
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ceruletide. Further studies are thus needed to elucidate the mechanisms by which ceruletide contributes to memory and cognitive functions.
PHARMACOKINETICS AND METABOLISM
The absorption, distribution, and metabolism of [ 35 S]ceruletide were studied in rats, rabbits, and mice (92) . Following an intramuscular injection, the radioactivity in the blood reached a maximum at 5 to 15 min and thereafter decreased rapidly. The biological activity of ceruletide for gall bladder contraction was detected in the blood collected up to 30 min after injection. The radioactivity in the brain, cecum, and colon paralleled that in the blood and decreased as rapidly as in the blood. The radioactivity in the kidneys, liver, pancreas, and stomach decreased more slowly. The highest radioactivity was found in the kidneys. The majority 60 -90% of the injected radioactive dose, was recovered in the urine within 24 h. Less than 5% was collected in the feces. No biological activity of ceruletide was measured in the urine.
At least four metabolites of ceruletide were detected in rat urine (92) . None of the metabolites had any biological activity. The rate-limiting step of the degradation of ceruletide may be the cleavage of 7 Trp- 8 Met bound by chymotrypsin. The most abundant radioactive metabolite was a peptide fragment of ceruletide. Ceruletide is reported to be more resistant to degradation than CCK-8 and other CCK-related peptides (104) .
In the brain, the rapid degradation of CCK-8 to inactive fragments may occur through membrane-bound aminopeptidase and enkephalinase, a neutral metalloendopeptidase (13) . When directly administered into the brain, ceruletide may also be degraded by the same enzymes.
TOXICOLOGY
A study of the acute toxicity of ceruletide in mice reported an i.v. LD 50 of 1,012 mg/kg (10) . Death occurred within a few minutes, probably due to cardiovascular collapse.
The chronic toxicity of ceruletide was studied in rats receiving 10, 50, and 250 µg/kg s.c. of ceruletide and in dogs receiving 2 and 6 µg/kg i.m. for up to 6 mo (10) . No mortality related to ceruletide treatment was observed. Only minimal histological changes in the pancreas, together with disruptions of fat absorption and a gain in body weight, were found following the highest dose of ceruletide treatment. Neither morphological nor histological abnormalities were discovered in any other organs. No behavioral changes in any animals were reported.
Reproduction studies were performed in rats and rabbits treated with 10-50 µg/kg of ceruletide throughout pregnancy (10) . There was no evidence of any adverse effect on the dams or teratologic action on the fetuses.
CLINICAL TRIALS Schizophrenia
The effects of ceruletide on schizophrenia have been reviewed elsewhere (60, 69) .
Briefly, preliminary open-label studies reported the favorable effects of ceruletide (0.3-2.0 µg/kg, i.m.; single or two doses in most of the studies) in patients with chronic schizophrenia medicated with antipsychotic drugs. Subsequent placebo-controlled, double-blind studies, however, failed to confirm the previously reported beneficial effects. Five of seven double-blind studies in patients with chronic schizophrenia medicated with antipsychotic drugs reported that ceruletide had no significant antipsychotic effect (0.3-0.8 µg/kg, i.m., for 4 d or weekly for 2-4 w). Two double-blind studies in patients with schizophrenia without any concomitant antipsychotic drugs also showed ceruletide to have no significant effect (0.3-1.5 µg/kg, i.m.; single dose or weekly for 4 w). Montgomery and Green (60), however, criticized the studies because they had short periods of treatment (not longer than 4 w), small numbers of subjects (N = 6-135), and limited sampling (i.e., chronic, stable, or refractory state with concomitant medication with antipsychotic drugs). They commented that the trial design used in these studies was too poor to draw any valid conclusions about the efficacy of ceruletide. This review would like to address the controversial issues that remain in regard to the clinical studies of ceruletide in schizophrenia.
First, the pharmacokinetics and BBB permeability of ceruletide do not support the long-lasting antipsychotic effects of ceruletide, as reported in some preliminary studies (69). Moroji et al. (65) reported that significant improvement was evident within 2 h following a single injection of ceruletide (0.3 or 0.6 µg/kg, i.m.) and thereafter continued for 3 w. The most significant effect was observed in the first week. Some subjects complained of abdominal discomfort, such as abdominal pain, nausea, and vomiting from 30 min to 1 h after ceruletide administration, but these peripheral effects disappeared within a few minutes. As previously mentioned, the biological activity of ceruletide in the blood disappears within 1 h after administration (92) . It therefore seems difficult to explain the longlasting antipsychotic effect of ceruletide in terms of the pharmacokinetics and bioavailability. Moreover, it is uncertain whether and how small doses of peripherally administered ceruletide for clinical use act in the CNS, as previously discussed in animal studies. Due to the discrepancy of peripheral adverse effects, however, it is unlikely that ceruletide may act primarily on the afferent vagal nerves in the visceral organs to exert a long-lasting effect. This problem still remains to be elucidated.
There is also no agreement on which types or symptoms of schizophrenia respond well to ceruletide. Most of the patients studied with ceruletide had chronic schizophrenia and were taking concomitant antipsychotic drugs. Preliminary studies have suggested that ceruletide might be effective on a certain aspect of negative symptoms of chronic refractory schizophrenia, while it had only limited effects on the disorganized type of schizophrenia characterized by prominent negative symptoms (60) . In this regard, Moroji et al. (64) reported a blunted response on the secretion of both growth hormone and luteinizing hormone in patients with schizophrenia who did not respond to ceruletide. The heterogeneity of the patient population may have contributed to the inconsistent results of the latter studies.
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Dyskinesia
Nishikawa et al. (71) first reported the beneficial effect of ceruletide on bucolingual symptoms in a patient with schizophrenia and tardive dyskinesia, using the measurements of electromyograms and microvibration. Oral movements were completely abolished 3 w after a single administration of ceruletide (0.8 µg/kg, i.m.), and this effect was still evident up to 6 w after injection. Ceruletide had no significant effect on psychotic symptoms in the patients. The additional studies confirmed the long-lasting inhibitory effects of a single injection of ceruletide on dyskinesia, while a temporary worsening effect was also observed in some patients (72) . Nishikawa et al. (73) further reported a favorable effect of repeated weekly administration of ceruletide (0.6 µg/kg, i.m.) on tardive dyskinesia.
Based on preliminary open-label, placebo-controlled, double-blind studies of the effects of ceruletide on tardive dyskinesia were performed in Japan. The research committee, sponsored by the Ministry of Health and Welfare, Japan, conducted the trials, and Shionogi & Co., Ltd., Osaka, Japan, supplied ceruletide for clinical use (86) .
A double-blind study in 37 chronic psychotic patients with tardive dyskinesia showed that ceruletide (0.8 µg/kg, i.m., weekly for 4 w) had a more profound effect on tardive dyskinesia than placebo, although it did not reach statistically significant levels probably due to the small sample size (57) . Ceruletide was more effective than placebo in patients under the age of 60 and with concomitant treatment with butyrophenone antipsychotics.
Another double-blind, matched-pairs study in 66 patients with tardive dyskinesia also reported on the inhibitory effects of ceruletide (0.8 µg/kg, i.m., weekly for 3 w) on tardive dyskinesia (45) . Global evaluations of the severity of tardive dyskinesia during an 8-w period revealed that the patients receiving ceruletide showed a significantly higher moderate-to-marked improvement rate (42%) compared to the patients receiving placebo (9%). The improvement became evident 5 w after the initiation of ceruletide injection, and it continued for more than 2 w. In line with the findings of preliminary studies, ceruletide thus produced a delayed but long-lasting effect on tardive dyskinesia. Although the results of two double-blind studies were favorable, further development of ceruletide for the treatment of tardive dyskinesia has been suspended due to the lack of sufficient knowledge on its unusual onset and duration of clinical effects.
The effects of ceruletide have been further examined on various other types of involuntary movement disorders. While Bruno et al. (9) failed to find any significant effect of ceruletide on Parkinson's disease, others reported a partial amelioration of tremors by ceruletide in patients with neurological disease (86) . Hashimoto and Yanagisawa (29) reported that ceruletide treatment causes an acute reduction and long-term improvement of choreic movement in patients with neurological diseases, including idiopathic orofacial dyskinesia and Huntington's disease. Furthermore, there have been a number of case reports on the beneficial effects of repeated weekly administration of ceruletide on various involuntary movement disorders, such as Meige's syndrome, palatal myoclonus with Behçet's disease, tardive dystonia, and tremors following thalamic hemorrhage (32, 39, 53) . In general, ceruletide has been reported to be more effective on dyskinesia and tremors than on dystonia and akinesia (86) . Most of the studies consistently reported long-lasting improvement of involuntary movement disorders. The improvement was maintained for 2-4 w after the last injection of ceruletide. It remains unclear whether or not such a long-lasting effect is similar to that observed in patients with schizophrenia.
The improvement of tardive dyskinesia in patients with schizophrenia was not associated with an amelioration of psychotic symptoms. Nevertheless, at present, the most proper indication of ceruletide should be as a treatment for dyskinesia and tremors. Yet further studies need to examine the efficacy of ceruletide in larger patient populations and also to elucidate the mechanism of its long-lasting action.
Senile Dementia
The subjects enrolled in the above-mentioned dyskinesia studies included a few patients with senile dementia. Some of the patients receiving ceruletide showed an improvement not only in the motor symptoms but also in the psychiatric symptoms associated with dementia. Preliminary open-label studies reported that ceruletide (0.8 µg/kg, i.m., once weekly for 6 w) was partially effective on both dementia of the Alzheimer type and multi-infarct dementia, as measured by Hasegawa's dementia rating scale, Mini-Mental State Examination (MMSE) and the Gottfries, Bråne, and Steen modified scale (87) . Although the ceruletide-induced improvement was noted especially in orientation, memory, attention and emotional functions, its effect on emotional functions was the most prominent. It is, therefore, uncertain whether or not ceruletide could primarily ameliorate the memory and cognitive functions. Biochemical examinations showed that acetylcholinesterase levels in the cerebrospinal fluid of the patients with senile dementia increased following ceruletide treatment, thus suggesting cholinergic augmentation (87) . Taken together with the antiamnestic effect of ceruletide in animal studies, these preliminary results suggest a possible effect of ceruletide on memory impairment of patients with senile dementia. However, no double-blind study in senile dementia with ceruletide has yet been performed.
Panic Disorder
As discussed based on the data from animal studies, ceruletide may have an anxiogenic effect by stimulating CCK B receptors. While CCK-4, a selective CCK B -receptor agonist, has been demonstrated to induce panic attack in humans (8) and cerebrospinal fluid CCK-8 concentrations in the patients with panic disorder were found to be significantly lower than in the normal comparison subjects (50), little is known about the effect of ceruletide on anxiety disorder. Early studies reported that ceruletide attenuates anxiety associated with histamine-induced headache in patients with psychogenic headache compared to placebo (6) . When used in cholecystography, ceruletide often causes nausea and abdominal discomfort and occasionally produces flushing, tachycardia, and dizziness (100). The latter symptoms might be consistent with the criteria for panic attack. However, these adverse effects are usually mild and self-limited and require no treatment. Dizziness and tachycardia often accompany the peripheral gastrointestinal effects and may, therefore, be secondary to them, although a direct central effect can not be excluded. 
CNS
CONCLUSIONS
Ceruletide has a variety of actions in the CNS, and its mechanism of action seems to be very complicated (Table 2 ). At present, the most favorable effect of ceruletide has been found in patients with dyskinesia and tremors. This fact suggests that ceruletide may influence the central dopaminergic systems to exert the major clinical effect. Recent evidence for CCK-dopamine interactions, however, does not support the earlier hypothesis that ceruletide might affect dopamine neurons only at the specific brain regions where CCK coexists with dopamine. Advances in the pharmacology of CCK-receptor subtypes have led to further understanding of the receptor-mediated interactions between CCK and dopamine in the widespread brain regions. As demonstrated in the nucleus accumbens and medial prefrontal cortex (12, 17) , ceruletide may have a modulatory effect on dopaminergic functions via interactions between CCK A and CCK B receptors. The differentiation of each receptor-specific effect of ceruletide may provide a clue to further pharmacological studies on the peptide. Furthermore, the possible protective effects of ceruletide on neurodegeneration, amnesia, and cognitive impairment may be useful for developing new treatments for neurodegenerative diseases, amnesic syndrome, and cognitive disorders. Even so, these effects might occur through nondopaminergic mechanisms.
Moreover, several questions have yet to be elucidated in the pharmacology of ceruletide. First, as discussed in this review, it still remains to be determined whether and how peripherally administered ceruletide at clinical doses could reach the human brain. Recent animal studies employing the selective CCK receptor antagonists suggest that a very small amount of peripherally administered ceruletide could enter the brain through the BBB. Second, if this is true, then it would also be possible that a small amount of the exogenous CCK peptide affects the activity of endogenous CCK to provoke a greater effect. Further studies await to investigate the possible interaction between ceruletide and endogenous CCK. Third, a number of both animal and human studies reported the long-lasting effects of ceruletide. So far no valid basic evidence could account for the mechanisms of these phenomena. The alterations of the intracellular transduction systems linked with CCK receptors may be involved. Further elucidation of the molecular basis for the actions of ceruletide would provide supportive evidence for its unique efficacy in the treatment of neuropsychiatric disease.
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